MarketCap
Facebook
X
Telegram
Viveve Medical Balance Sheet 2021-2009 | VIVE
Brief overview of Viveve Medical's financial position
Balance sheet changes are traced across five available annual reports between 2017 and 2021.
The asset base decreased -28.2%, from $36.1 million to $25.9 million. Resources became smaller over the five periods.
Growth in the asset base was not matched by liabilities: -28.2% versus -72%. The balance sheet moved in a more conservative direction.
The equity ratio reached 58.1% from -7.2%. A high capital share reduces dependence on liabilities.
Cash equals 73.9% of the balance sheet, compared with 57.5% five periods ago. This is the readily available cushion.
The accumulated result is -$241.9 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Overall picture
Viveve Medical's financial position is more positive than negative: the funding mix is workable, although the cushion is not unlimited.
Annual Balance Sheet Viveve Medical
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -6.1 M | -7.32 M | 18.4 M | 29.8 M | -324 K | -2.15 M | 1.88 M | 4.11 M | 7.65 M | 2.74 M | - | - |
Long Term Debt |
- | 425 K | 5.99 M | 47.9 M | 50.5 M | 7.76 M | 5.21 M | 2.77 M | 4.54 M | 8.1 M | 5.33 M | - | - |
Total Non Current Liabilities |
- | 498 K | 4.15 M | 31.2 M | 29.3 M | 7.82 M | - | - | 7.22 M | 11.9 M | 6.93 M | - | - |
Total Current Liabilities |
4.53 M | 4.22 M | 6.31 M | 10.8 M | 9.4 M | 7.14 M | 7.17 M | 3.14 M | 7.82 M | 1.14 M | 710 K | 1.88 M | - |
Total Liabilities |
10.8 M | 9.66 M | 10.5 M | 41.9 M | 38.7 M | 15 M | 7.17 M | 3.14 M | 8.44 M | 13 M | 7.64 M | - | - |
Deferred Revenue |
- | - | 108 K | 686 K | - | - | - | - | - | 317 K | 277 K | 98 K | - |
Retained Earnings |
-242 M | -220 M | -198 M | -155 M | -106 M | -68.6 M | -48.5 M | -36.1 M | -29.9 M | -107 M | -98.7 M | -93 M | - |
Total Assets |
25.9 M | 16.6 M | 27 M | 46.8 M | 36.1 M | 14.5 M | 11.1 M | 2.3 M | 1.14 M | 1.09 M | 3.55 M | 3.32 M | - |
Cash and Cash Equivalents |
19.2 M | 6.52 M | 13.3 M | 29.5 M | 20.7 M | 8.09 M | 7.36 M | 895 K | 430 K | 449 K | 2.58 M | 1.32 M | 2.69 M |
Book Value |
15.1 M | 6.97 M | 16.5 M | 4.91 M | -2.6 M | -405 K | 3.94 M | -841 K | -7.31 M | -11.9 M | -4.09 M | 3.32 M | - |
Total Shareholders Equity |
15.1 M | 6.97 M | 16.5 M | 4.91 M | -2.6 M | -405 K | 3.94 M | -841 K | -7.31 M | -3.08 M | -4.09 M | 1.43 M | 1.73 M |
All numbers in USD currency
Quarterly Balance Sheet Viveve Medical
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | 97 K | 425 K | 679 K | 784 K | 5.99 M | 5.99 M | 45.8 M | 46.5 M | 47.2 M | 47.9 M | 48.6 M | 49.2 M | 49.9 M | 50.5 M | 34.4 M | 34.8 M | - | - | - | - | 4.85 M | 5.21 M | 5.45 M | 4.36 M | 3.85 M | 2.77 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | 11 M | 10.2 M | 10.5 M | 10.8 M | 10 M | 8.91 M | 10.1 M | 9.66 M | 8.84 M | 9.9 M | 8.88 M | 10.5 M | 38.9 M | 39.2 M | 39.4 M | 41.9 M | 39.2 M | 40.2 M | 37.7 M | 38.7 M | 26.2 M | 23.9 M | 15.2 M | 15 M | 14 M | 13.5 M | 8.23 M | 7.17 M | 6.93 M | 5.6 M | 4.7 M | 3.14 M | 2.43 M | 3.14 M | 3.14 M | 8.44 M | 8.45 M | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | 108 K | 470 K | 552 K | 679 K | 686 K | 334 K | 182 K | 686 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 108 K | - | - | 13 K | 51 K | 248 K | 317 K | 394 K | 256 K | 285 K | 277 K | 98 K | 98 K | 277 K |
Retained Earnings |
- | -259 M | -254 M | -248 M | -242 M | -236 M | -230 M | -226 M | -220 M | -215 M | -211 M | -204 M | -198 M | -183 M | -175 M | -165 M | -155 M | -142 M | -130 M | -118 M | -106 M | -95.4 M | -85.7 M | -75.3 M | -68.6 M | -62.8 M | -57.9 M | -52.6 M | -48.5 M | -44.8 M | -41.6 M | -38.6 M | -36.1 M | 34.3 M | -104 M | -106 M | -29.9 M | -108 M | -107 M | -115 M | -107 M | -110 M | -107 M | -106 M | -98.7 M | -97.7 M | -97.3 M | -98.7 M |
Total Assets |
- | 12.2 M | 15.5 M | 20.7 M | 25.9 M | 30.4 M | 34 M | 37.7 M | 16.6 M | 19.9 M | 20.5 M | 21.4 M | 27 M | 24.1 M | 25.5 M | 34.9 M | 46.8 M | 36.4 M | 48.9 M | 56.6 M | 36.1 M | 33.1 M | 39.9 M | 40 M | 14.5 M | 19.1 M | 23.1 M | 8.66 M | 11.1 M | 8.93 M | 10.8 M | 1.63 M | 2.3 M | 3.15 M | 721 K | 604 K | 1.14 M | 2.48 M | 2.28 M | 3.57 M | 1.09 M | 1.79 M | 1.84 M | 2.55 M | 3.55 M | 4.02 M | 4.95 M | 3.55 M |
Cash and Cash Equivalents |
- | 5.91 M | 9.43 M | 14 M | 19.2 M | 22.7 M | 25.4 M | 28.4 M | 6.52 M | 9.2 M | 8.5 M | 9.04 M | 13.3 M | 9.09 M | 9.51 M | 17.8 M | 29.5 M | 20.1 M | 30.2 M | 38.4 M | 20.7 M | 19.2 M | 31.1 M | 31.4 M | 8.09 M | 14 M | 19.9 M | 5.01 M | 7.36 M | 6.06 M | 8.36 M | 221 K | 895 K | 1.98 M | 87 K | 128 K | 430 K | 1.4 M | 1.13 M | 1.86 M | 449 K | 723 K | 997 K | 1.6 M | 2.58 M | 3.17 M | 4.06 M | 2.58 M |
Book Value |
- | 1.18 M | 5.28 M | 10.2 M | 15.1 M | 20.4 M | 25.1 M | 27.5 M | 6.97 M | 11.1 M | 10.6 M | 12.6 M | 16.5 M | -14.8 M | -13.7 M | -4.59 M | 4.91 M | -2.77 M | 8.7 M | 19 M | -2.6 M | 6.86 M | 16 M | 24.8 M | -405 K | 5.06 M | 9.56 M | 436 K | 3.94 M | 2 M | 5.15 M | -3.06 M | -841 K | 724 K | -2.42 M | -2.54 M | -7.31 M | -5.96 M | 2.28 M | 3.57 M | 1.09 M | 1.79 M | 1.84 M | 2.55 M | 3.55 M | 4.02 M | 4.95 M | 3.55 M |
Total Shareholders Equity |
- | 1.18 M | 5.28 M | 10.2 M | 15.1 M | 20.4 M | 25.1 M | 27.5 M | 6.97 M | 11.1 M | 10.6 M | 12.6 M | 16.5 M | -14.8 M | -13.7 M | -4.59 M | 4.91 M | -2.77 M | 8.7 M | 19 M | -2.6 M | 6.86 M | 16 M | 24.8 M | -405 K | 5.06 M | 9.56 M | 436 K | 3.94 M | 2 M | 5.15 M | -3.06 M | -841 K | 724 K | -5.78 M | -9.02 M | -7.31 M | -10.6 M | -9.73 M | -19.3 M | -3.08 M | -15.1 M | -12 M | -10.7 M | -4.09 M | -3.17 M | -2.78 M | -4.09 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Viveve Medical, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Britain
Israel
Canada
China
